Drug Profile


Alternative Names: R-7128; RG 7128; RG7320; RO 5024048

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmasset
  • Developer Roche
  • Class Antivirals; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA-directed RNA polymerase inhibitors; Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 12 Feb 2016 Roche terminates a phase II trial in Hepatitis C in USA, Australia, Austria, Brazil, Canada, France, Germany, Italy, Mexico, New Zealand, Poland, Puerto Rico, Slovakia, Spain and United Kingdom due to decrease in percentage of participants (NCT01168856)
  • 28 Jan 2015 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-experienced) in Australia, Canada, USA, Brazil, Mexico, Germany, France, Spain, Puerto Rico, Poland, New Zealand, Slovakia, United Kingdom, Austria, Italy (PO)
  • 28 Jan 2015 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in Germany, France, Italy, Puerto Rico, Canada, USA, Australia, Poland, Austria, United Kingdom, Spain, New Zealand (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top